The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.

In vitro data have recently suggested that sulfonylureas (SUs) enhance GH secretion by modulating the effects of GHRH and somatostatin in pituitary cells. The present study was undertaken to explore in more detail a possible influence of a single dose of SU (glibenclamide) and a non-SU (repaglinide) insulin secretagogue on circulating GH dynamics. Ten C-peptide-negative type 1 diabetic individuals were examined on three occasions in random order. Either glibenclamide (10.5 mg), repaglinide (8 mg), or placebo was administered after overnight normalization of plasma glucose by iv insulin infusion. Subsequently, GH concentrations were measured regularly after stimulation with GHRH (bolus 0.1 micro g/kg) alone and during concomitant infusion with somatostatin (7 ng.kg(-1).min(-1)). Insulin was replaced at baseline levels (0.25 mU.kg(-1).min(-1)) and plasma glucose clamped at 5-6 mmol/liter. Overall, there were no significant statistical differences in GH responses determined as either GH peak concentrations, integrated levels of GH, or secretory burst mass of GH during the experimental protocol. In contrast, plasma glucagon concentrations were significantly increased during glibenclamide and repaglinide exposure. The present experimental design does not support the hypothesis that acute administration of pharmacological doses of the oral antihyperglycemic agents glibenclamide and repaglinide per se enhance GH release in humans. Additionally, this study shows that these potassium channel inhibitors seem to stimulate glucagon secretion in people who have severe intraislet insulin deficiency (e.g. type 1 diabetes). However, extrapolation of our findings to type 2 diabetic individuals should be done with some caution.

[1]  J. Campbell,et al.  Somatotrophic diabetes: Insulin release responses to arginine and glucagon in dogs , 1978, Diabetologia.

[2]  F. Ashcroft,et al.  Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. , 2002, Diabetes.

[3]  P. Rorsman,et al.  Nateglinide, but not repaglinide, stimulates growth hormone release in rat pituitary cells by inhibition of K channels and stimulation of cyclic AMP-dependent exocytosis. , 2002, European journal of endocrinology.

[4]  A. Avogaro,et al.  Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. , 2002, Diabetes.

[5]  I. van der Tweel,et al.  The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia. , 2002, Diabetes care.

[6]  P. Rorsman,et al.  Patch‐clamp characterisation of somatostatin‐secreting δ‐cells in intact mouse pancreatic islets , 2000, The Journal of physiology.

[7]  P. Rorsman,et al.  Tolbutamide stimulates exocytosis of glucagon by inhibition of a mitochondrial‐like ATP‐sensitive K+ (KATP) conductance in rat pancreatic A‐cells , 2000, The Journal of physiology.

[8]  L. Howes.  Cardiovascular effects of sulphonylureas: role of KATP channels , 2000, Diabetes, obesity & metabolism.

[9]  J. Holst,et al.  Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells. , 1999, European journal of pharmacology.

[10]  U. Adamson,et al.  Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. , 1999, The Journal of clinical endocrinology and metabolism.

[11]  P. Rorsman,et al.  Characterisation of sulphonylurea and ATP-regulated K+ channels in rat pancreatic A-cells , 1999, Pflügers Archiv.

[12]  F. Ashcroft,et al.  ATP-sensitive K+ channels and insulin secretion: their role in health and disease , 1999, Diabetologia.

[13]  A. Terzic,et al.  Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. , 1999, Journal of the American College of Cardiology.

[14]  P. Rorsman,et al.  Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. , 1998, Diabetes.

[15]  A. Caumo,et al.  Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects. , 1997, The Journal of clinical endocrinology and metabolism.

[16]  G. Tucker,et al.  The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans. , 1997, The Journal of clinical endocrinology and metabolism.

[17]  Olof Larsson,et al.  PKC-Dependent Stimulation of Exocytosis by Sulfonylureas in Pancreaticβ Cells , 1996, Science.

[18]  A. Berts,et al.  Suppression of Ca2+ oscillations in glucagon-producing alpha 2-cells by insulin/glucose and amino acids. , 1996, Biochimica et biophysica acta.

[19]  R. Rizza,et al.  The Role of Growth Hormone in the Development of Diabetic Retinopathy , 1994, Diabetes Care.

[20]  U. Smith,et al.  Effect of prolonged hyperglycemia on growth hormone levels and insulin sensitivity in insulin-dependent diabetes mellitus. , 1993, Metabolism: clinical and experimental.

[21]  M. Lazdunski,et al.  ATP-modulated K+ channels sensitive to antidiabetic sulfonylureas are present in adenohypophysis and are involved in growth hormone release. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Lazdunski,et al.  Effectors of ATP-sensitive K+ channels inhibit the regulatory effects of somatostatin and GH-releasing factor on growth hormone secretion. , 1992, Biochemical and biophysical research communications.

[23]  L. Groop.  Sulfonylureas in NIDDM , 1992, Diabetes Care.

[24]  N. Møller,et al.  Effects of growth hormone on fuel utilization and muscle glycogen synthase activity in normal humans. , 1991, The American journal of physiology.

[25]  A. Flyvbjerg.  Growth Factors and Diabetic Complications , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[26]  K. Polonsky,et al.  Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. , 1989, The Journal of clinical endocrinology and metabolism.

[27]  D. Garrel,et al.  Effect of sustained hyperglycemia on GHRH induced GH secretion in man. , 1989, Diabete & metabolisme.

[28]  M L Johnson,et al.  The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Golay,et al.  Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. , 1987, The Journal of clinical endocrinology and metabolism.

[30]  F. Umeda,et al.  Effect of glibenclamide on pancreatic hormone release from isolated perifused islets of normal and cysteamine-treated rats. , 1986, Metabolism: clinical and experimental.

[31]  K. Alberti,et al.  Aspects of glucose homeostasis in uremia as assessed by the hyperinsulinemic euglycemic clamp technique. , 1985, Metabolism: clinical and experimental.

[32]  N. Ling,et al.  The effect of glucose on growth hormone (GH)-releasing hormone-mediated GH secretion in man. , 1985, The Journal of clinical endocrinology and metabolism.

[33]  N. Ling,et al.  The effect of free fatty acids on growth hormone (GH)-releasing hormone-mediated GH secretion in man. , 1985, The Journal of clinical endocrinology and metabolism.

[34]  W. Tamborlane,et al.  Pituitary Response to Growth Hormone–releasing Factor in Diabetes: Failure of Glucose-mediated Suppression , 1984, Diabetes.

[35]  E. Kohner,et al.  THE EFFECT OF PLASMA GLUCOSE ON THE GROWTH HORMONE RESPONSE TO HUMAN PANCREATIC GROWTH HORMONE RELEASING FACTOR IN NORMAL SUBJECTS , 1984, Clinical endocrinology.

[36]  R. Unger.  Insulin-Glucagon Relationships in the Defense Against Hypoglycemia , 1983, Diabetes.

[37]  L. Mandarino,et al.  Effects of Growth Hormone on Insulin Action in Man: Mechanisms of Insulin Resistance, Impaired Suppression of Glucose Production, and Impaired Stimulation of Glucose Utilization , 1982, Diabetes.

[38]  M. Lorenzi,et al.  Stimulatory effects of tolbutamide infusion on plasma glucagon in insulin-dependent diabetic subjects. , 1982, The Journal of clinical endocrinology and metabolism.

[39]  S. Efendić,et al.  Effect of glucose/sulfonylurea interaction on release of insulin, glucagon, and somatostatin from isolated perfused rat pancreas. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Grodsky,et al.  Pancreatic action of the sulfonylureas. , 1977, Federation proceedings.

[41]  R. Unger,et al.  Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide. , 1977, The Journal of clinical investigation.

[42]  H. Bratzke,et al.  Studies on the relationship between plasma free fatty acids and growth hormone secretion in man. , 1972, The Journal of clinical investigation.

[43]  C. Meinert,et al.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. , 1970, Diabetes.